SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-034230
Filing Date
2024-03-20
Accepted
2024-03-20 16:42:54
Documents
12
Period of Report
2024-03-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20240315.htm   iXBRL 8-K 54477
2 EX-10.1 virx-ex10_1.htm EX-10.1 137299
  Complete submission text file 0000950170-24-034230.txt   326359

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240315.xsd EX-101.SCH 23862
16 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240315_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 24768320
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)